

Institutional Review Board

Re-Consent or Notification of Significant New Findings Developed During the Course of Research Policy - Arizona, Florida, Rochester

Scope

Mayo Clinic Human Research Protection Program

Purpose

The IRB may determine that research subjects must receive additional information about changes or findings that may affect the subject and/or their willingness to continue participation in the research. Determining the plan to inform each subject requires careful consideration of several factors. The purpose of this document is to provide investigators with guidance about notification requirements.

Policy

The IRB has the authority to require investigators to re-consent or notify subjects if new information related to the study becomes available, new risks are identified, significant study alterations are made, or the initial consent process was inadequate.

IRB Responsibilities

- The IRB is responsible for determining when re-consent or other notification of subjects is required.
- The IRB may determine that re-consent or other notification is required for some or all of the subjects of the research project.

Investigator Responsibilities

- Inform the IRB, via an electronic IRB Modification form according to specified timelines, of any new information or changes in study design or procedures that might have an impact on any subject's willingness to continue in the study. The modification request should include the Subject Notification Form attachment.
- Re-consent or notify the subjects, as required by the IRB.
- Re-consent subjects prior to their involvement in the procedural change.
- For increased study risks, re-consent the subjects within 30 days after availability of the IRB approved updated consent document. The changed risks should be highlighted in the consent document presented to the subject.
- When mailing the consent document for subject's signature, summarize in an informational cover letter the changes or additions that have been made to the consent document.
- Submit informational cover letters for IRB approval. For efficiency, include the letter in the same modification as the revised consent form.
- Report the status of required subject re-consenting/notification activities at the time of continuing review.

Considerations for Notification of Subjects

The table below lists questions and considerations to aid in determining notification requirements. Once the requirements are determined, recommended options for implementing the notification based on participant status may be found in the second table, Determining Methods of Notification.

<p>1. Who needs to be notified or re consented?</p> <ul style="list-style-type: none"> • Subjects actively undergoing research intervention • All subjects • Subset of subjects 	<ul style="list-style-type: none"> • Does the change affect subjects differently? • If yes, clearly define each subset affected differently by the change (i.e. males, females, specific age groups, subjects in active treatment, specific study arm, subjects off study, etc.)
<p>2. What is the change that requires communication?</p> <ul style="list-style-type: none"> • Additional risks or change in risk severity or frequency • Change in level of discomfort or other inconvenience • Procedural changes including remuneration or reimbursement • New alternative options available • Other 	<ul style="list-style-type: none"> • Could the change affect a subjects decision to remain in the study? • Regulatory, ethical or policy requirements • New research findings at Mayo or elsewhere • Will the change involve a different level of commitment from the subject?
<p>3. When must notification or re consent occur to protect subject safety and rights (regardless of logistics)?</p> <ul style="list-style-type: none"> • Immediate • Before next study visit • Before specific study procedures • Within specified time period • Varies with affected participant subset • Alternate plan if revised consent version not yet available when needed for subject 	<ul style="list-style-type: none"> • Are subjects coming in for visits or are study procedures done at home? • Are subjects impacted now or in the future? • Are subjects who have completed study procedures/visits impacted? • Logistics (including any travel, expense or inconvenience to subjects)
<p>4. Where and How should notification be implemented?</p> <ul style="list-style-type: none"> • Phone • Letter • Letter with phone follow-up • Revised consent form • In-person visit 	<ul style="list-style-type: none"> • Complexity and need for interactive explanation and discussion • Need for physical demonstration or other presentation of information best done in person • Timeline for next subject visit • Verification of subject identity if not consented in person • Any subject limitations such as age, disabilities, language, level of understanding, vulnerable population

Determining Methods of Notification - Based on Study Participant Status

Study Participant still active in study	
Participant Affected by Changes	Participant Not Affected by Changes
<p>Examples:</p> <ul style="list-style-type: none"> • New risk or increase risk of drug • New risk or increased risk of procedure subject will undergo • Changes to remuneration/reimbursement 	<p>Examples:</p> <ul style="list-style-type: none"> • New procedure that the subject will not undergo (such as at baseline) • Arm/treatment not affected by change or risk (on a different treatment) • Subgroup not affected (women only - pregnancy testing)
<p>Method of Notification:</p> <ul style="list-style-type: none"> • Re-consent • If next study visit is greater than 30 days, notify via phone or letter, re-consent at next in-person visit 	<p>Method of Notification:</p> <ul style="list-style-type: none"> • Typically, no notification needed
Study Participant has completed procedures and all study visits	
Participant Affected by Changes	Participant Not Affected by Changes
<p>Examples:</p> <ul style="list-style-type: none"> • Newly identified long term or late-occurring risk 	<p>Examples:</p> <ul style="list-style-type: none"> • Changes to procedure or protocol • Newly identified immediate, short-lasting risk
<p>Method of Notification:</p> <ul style="list-style-type: none"> • Letter to notify of potential long term or late-occurring risk • Phone 	<p>Method of Notification:</p> <ul style="list-style-type: none"> • Typically, no notification needed

Policy Notes

N/A

Related Procedure(s)

[Modifications to Previously Approved or Exempt Research](#)

Related Document(s)

[Reporting Timelines for IRB Submission when Mayo Clinic is Serving as the IRB of Record](#) (IRB 10539)

[Subject Notification Form](#) (IRB 10542)

[Risk Notification Letter template](#) (IRB 10543)

Definitions

Re-Consent: Process of notifying research subjects of changes in the research including documentation of the subject's continued informed consent through signature on a revised written consent form.

Notification: Process of notifying research subjects of changes in the research by letter or phone, or during an in-person visit.

References

N/A

Owner

Tammy Neseth on behalf of Mayo Clinic Human Research Protection Program

Contact

Michelle Daiss, Angela Patterson

Revision History

Date	Synopsis of Change
05/03/2019	Scheduled review - changed owner to Tammy Neseth
7/13/2018	Clarified that reconsent for increased risks is required within 30 days of availability of IRB-approved updated consent document.
June 1, 2018	Revised to be consistent with IRB Submission Timelines. Added Subject Notification Form and Risk Notification Letter Template
10/07/2016	Scheduled Review - updated to current template format no content changes

[Content Information](#)

Notification Recipient: Kuntz, Melissa M.
Content ID: DOCMAN-0000047845
Effective Date of Current Version: 05/03/2019
Site(s): Rochester, Arizona, Florida

Workflow Reviewer Name(s): Daiss, Michelle K.
Workflow Approver Name(s): Neseth, Tammy S., M.A.
Scheduled Review Due Date: 04/30/2021

Comments: Clarified that reconsent for increased risks is required within 30 days of availability of IRB-approved updated consent document. Updated Notification Term.

COPYRIGHT © Mayo Foundation for Medical Education and Research. This information is intended for use by employees of Mayo Clinic and its subsidiaries only. It is confidential and no part of it may be transmitted in any form by electronic, mechanical, photocopying, or any other means to anyone outside Mayo Clinic without the prior permission of Mayo Foundation for Medical Education and Research. Inappropriate use or dissemination of this information may result in disciplinary action.

Master copies are retained online. Printed copies are considered current only on the date printed.